Research Topics
| D PodzamczerSummaryAffiliation: Hospital Universitari de Bellvitge Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized studyDaniel Podzamczer
Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
J Acquir Immune Defic Syndr 44:139-47. 2007..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...- Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study GroupD Podzamczer
Infectious Disease Service, Ciutat Sanitaria de Bellvitge, c Feixa Llarga s n L Hospitalet, Barcelona, Spain
Eur J Clin Microbiol Infect Dis 19:89-95. 2000..Administration of antiretroviral therapy was the only factor associated with a lower incidence of relapse... - Early virological failure with a combination of tenofovir, didanosine and efavirenzDaniel Podzamczer
Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
Antivir Ther 10:171-7. 2005..To describe the occurrence of a high early virological failure (VF) rate and development of resistance mutations in antiretroviral-naive patients receiving tenofovir, didanosine and efavirenz... - How much fat loss is needed for lipoatrophy to become clinically evident?Daniel Podzamczer
Infectious Disease Service, Hospital Universitari de Bellvitge, c Feixa Llarga s n L Hospitalet, Barcelona 08907, Spain
AIDS Res Hum Retroviruses 25:563-7. 2009..5 kg (sensitivity, 77%; specificity, 76%) and -30% (sensitivity, 85%; specificity, 73%). At least 30% limb fat is needed to be lost in HIV-infected patients for lipoatrophy to become clinically evident... - Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed PatientsDaniel Podzamczer
Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
J Acquir Immune Defic Syndr 50:390-6. 2009..The strategy of switching nevirapine (NVP) twice daily to once daily was evaluated... - A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)Daniel Podzamczer
Infectious Disease Service, Ciutat Sanitaria de Bellvitge, L Hospitalet, Barcelona, Spain
Antivir Ther 7:81-90. 2002.... - The role of nevirapine in the treatment of HIV-1 diseaseD Podzamczer
Infectious Disease Service, Ciutat Sanitaria de Bellvitge, Barcelona, Spain
Expert Opin Pharmacother 2:2065-78. 2001..Hepatotoxicity may also appear with nevirapine, mainly in patients with chronic hepatitis C and/or altered liver function tests. This side effect may occasionally be life-threatening but it can be safely managed in most patients... - Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapineElena Ferrer
Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
J Infect Dis 187:687-90. 2003..At failure, mutations were detected in 7 of 16 patients. An agreement in the results of virtual and real phenotypes was observed in the 93 samples in which both tests were performed... - High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of responseDaniel Podzamczer
Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
HIV Clin Trials 8:193-204. 2007..To investigate the efficacy and safety of high-dose lopinavir/ritonavir (LPV/r) therapy in multiple protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced subjects... - Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyEsteban Martinez
Infectious Diseases Unit, Hospital Clínic Institut d Investigaciones Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
AIDS 24:1697-707. 2010..Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result in similar efficacy and lower plasma lipids... - Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy)A Casado
University of Barcelona, Barcelona, Spain
HIV Clin Trials 5:132-9. 2004..CONCLUSION: Differences in HRQoL between study groups at 1 year follow-up were not detected. Nevertheless, a trend toward improvement was observed in summary health scores in ZDV/3TC/NVP-treated patients... - Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patientsA Casado
Unitat de Recerca en Resultats Sanitaris, Departament d Epidemiología Clínica y Salut Pública, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain
HIV Clin Trials 2:477-83. 2001.... - Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP studyJosep Mallolas
Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
J Acquir Immune Defic Syndr 51:29-36. 2009..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r... - Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapyXavier Badia
Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Antivir Ther 9:979-85. 2004..To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen... - HIV-1 infected patients older than 50 years. PISCIS cohort studyG Navarro
Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
J Infect 57:64-71. 2008..The aim of this study is to characterize the ways in which older HIV-infected people differ from younger HIV-infected people... - Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study GroupJ M Gatell
Hospital Clinic, Barcelona, Spain
J Acquir Immune Defic Syndr Hum Retrovirol 12:249-58. 1996..This effect tended to be greater among individuals with higher CD4 counts (>100/mm3)... - Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz TJose M Miro
Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
AIDS Res Hum Retroviruses 26:747-57. 2010..At 1 and 3 years, the immune reconstitution induced by an efavirenz-based regimen in very immunosuppressed patients was at least as potent as that induced by a ritonavir-boosted protease inhibitor-based antiretroviral regimen... - Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patientsEsteban Martinez
Hospital Clinic, Barcelona, Spain
AIDS 21:367-9. 2007..In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation... - Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapineMontserrat Plana
Institut Clinic d Infeccions i Immunologia, Immunology, Infectious Diseases and Microbiology Units, Institut de Investigació Biomèdica Agusti Pi i Suñer, Hospital Clinic, University of Barcelona, Barcelona, Spain
Antivir Ther 9:197-204. 2004..To evaluate the immunological response in HIV-1-infected, antiretroviral-naive patients receiving highly active antiretroviral therapy regimen of two nucleosides plus a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor... - Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)M Saumoy
Infectious Disease Service, Bellvitge University Hospital, Sant Pau Hospital and Autonomous University, Barcelona, Spain
HIV Med 12:438-41. 2011..The aim of the study was to evaluate the efficacy of fosamprenavir/ritonavir (FPV/r) monotherapy in plasma and reservoirs in virologically suppressed patients... - Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 diseaseM Santin
Department of Infectious Diseases, IDIBELL, Hospital Universitari de Bellvitge, University of Barcelona, c Feixa Llarga s n, 08907, L Hospitalet, Barcelona, Spain
Eur J Clin Microbiol Infect Dis 27:65-73. 2008..However, as good control of viral replication is maintained, satisfactory long-term immune restoration can nonetheless be achieved... - Objective amount of limb fat in HIV-infected subjects with subjective diagnosis of lipoatrophyE Martinez
Infectious Diseases Unit, Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
HIV Med 10:257-61. 2009..The relationship between the subjective diagnosis of lipoatrophy and the objective amount of limb fat loss in HIV-infected adults is unclear... - New patterns of HIV-1 resistance during HAARTE Fumero
Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
Clin Microbiol Infect 9:1077-84. 2003..Resistance to the new entry inhibitor class compound T-20 (enfuvirtide) has also been detected... - Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or lessElena Ferrer
Infectious Disease Services, Universitari de Bellvitge Hospital, Barcelona, Spain
AIDS 18:1727-9. 2004..More than 80% of patients who continued with nevirapine had viral loads < 50 copies/ml and CD4 cell counts > 200 cells/pl... - Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortalityMiriam J Alvarez-Martinez
Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
Diagn Microbiol Infect Dis 62:34-43. 2008..03 and P < 0.001, respectively). The prevalence of DHPS mutants in Spain is low and is not associated with a worse outcome. Severe respiratory failure at admission is the strongest predictor of PCP outcome... - Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal diseaseI Grau
Infectious Disease Service, IDIBELL, CibeRes, Hospital Bellvitge, University of Barcelona, Barcelona, Spain
HIV Med 10:488-95. 2009..The aim of the study was to describe trends and risk factors for mortality and changes in antibiotic resistance, serotypes and clones among HIV-infected patients with invasive pneumococcal disease (IPD)... - Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot studyElena Ferrer
Infectious Disease and Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
AIDS Res Hum Retroviruses 24:931-4. 2008..Larger trials comparing this option with standard initial antiretroviral regimens should be conducted... - Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatmentPatricia Barragan
Hospital Universitari de Bellvitge, Feixa Llarga s n L Hospitalet de Llobregat, 08907, Barcelona, Spain
Expert Opin Pharmacother 9:2363-75. 2008..Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection... - A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled studyCesar Fisac
Endocrinology Services, Hospital Universitario de Bellvitge, 08907 L Hospitalet de Llobregat, Barcelona, Spain
J Clin Endocrinol Metab 88:5186-92. 2003..Inclusion of NVP should be considered when deciding upon antiretroviral regimens for patients at high coronary risk... - Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppressionJose R Santos
Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
HIV Clin Trials 10:432-8. 2009..To assess the Efficacy and safety of switching from HAART containing enfuvirtide to raltegravir as a simplification strategy in patients with viral suppression and intolerance to enfuvirtide... - Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapineCesar Fisac
Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
AIDS 19:917-25. 2005..To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir... - A review of nelfinavir for the treatment of HIV infectionMontserrat Olmo
Hospital Universitario de Bellvitge, Infectious Diseases Service, HIV Unit, Hospitalet de Llobregat, Barcelona, Spain
Expert Opin Drug Metab Toxicol 2:285-300. 2006..In addition, its new simplified posology may contribute to improved adherence... - Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter studyVicenc Falco
Infectious Disease Department, Hospital Universitario Vall d Hebron, Barcelona, Spain
J Acquir Immune Defic Syndr 49:26-31. 2008.... - Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapyImma Grau
Infectious Disease Service, Clinical Research Unit, IDIBELL-Hospital de Bellvitge and University of Barcelona, Barcelona, Spain
Arch Intern Med 165:1533-40. 2005..Risk factors and prognosis of pneumococcal bacteremia in the HAART era are more similar to those reported in non-HIV-infected individuals... - Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trialJose M Miro
Institut d Investigacions Biomediques August Pi Sunyer Hospital Clinic, University of Barcelona, Barcelona, Spain
Clin Infect Dis 43:79-89. 2006..To our knowledge, no randomized trials have evaluated whether prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count increases in response to highly active antiretroviral therapy... - Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, SpainM Santin
Department of Infectious Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain
Epidemiol Infect 132:425-32. 2004..kansasii disease in our area. M. kansasii disease in our geographical area was almost exclusively caused by subtype I regardless of HIV status... - Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patientPatricia Barragan
Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
Am J Trop Med Hyg 83:10-2. 2010..We report the case of a human immunodeficiency virus-1-infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy... - Switching strategies to improve lipid profile and morphologic changesPatricia Barragan
Infectious Disease Service, Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain
AIDS Rev 8:191-203. 2006..In this setting, switching strategies may be useful to minimize clinical and psychological consequences, improving the quality of life of HIV-infected patients treated with HAART... - [Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients]Daniel Podzamczer
, L'Hospitalet, Barcelona, Spain
Med Clin (Barc) 118:788-95. 2002 - Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patientsArkaitz Imaz
HIV Unit, Infectious Diseases Service, Hospital Universitari de Bellvitge, Barcelona, Spain
AIDS Rev 12:153-63. 2010..This article summarizes the current knowledge regarding associated risk factors, clinical manifestations, and management of community-acquired methicillin-resistant Staphylococcus aureus infections in HIV-infected patients... - Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohortJuan Berenguer
Infectious Diseases and HIV Unit, Hospital Gregorio Maranon, Madrid, Spain
J Acquir Immune Defic Syndr 41:154-9. 2006..To analyze the safety and effectiveness of abacavir, lamivudine, and zidovudine (ABC/3TC/ZDV) in antiretroviral therapy (ART)-naive HIV-infected patients... - [Validation of a questionnaire to estimate satisfaction with antiretroviral treatment: CESTA questionnaire]Emilia Condes
Servicio de Medicina Interna, , Madrid, Spain
Enferm Infecc Microbiol Clin 23:586-92. 2005..CONCLUSIONS: The CESTA questionnaire is a valid instrument for use in clinical practice and provides valuable information on patient satisfaction with antiretroviral therapy... - Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz
Hospital Clinic-IDIBAPS, University of Barcelona, Spain
AIDS 17:831-40. 2003..However, the IDV q8h arm performed better when discontinuations were classified as failures. IDV/RTV q12h can be convenient and equally effective for patients able to tolerate it... - [Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]Ana María Caro-Murillo
Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
Enferm Infecc Microbiol Clin 25:23-31. 2007..To describe the methodology and baseline results of the Spanish cohort of naïve HIV-infected patients included in the Research Network on HIV/AIDS (CoRIS)... - Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infectionEsteban Martinez
Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
N Engl J Med 349:1036-46. 2003..We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved... - A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenMargaret A Johnson
Royal Free Center for HIV Medicine, London, United Kingdom
J Acquir Immune Defic Syndr 43:153-60. 2006..Both regimens were relatively well tolerated, and no LPV or TDF resistance was observed... - Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcomaLuz Martin-Carbonero
AIDS 18:1737-40. 2004..After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%).In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response... - Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)Angeles Jaén
Centre d Estudis Epidemiològics sobre ITS VIH SIDA de Catalunya, Badolona, Spain CEEISCAT, Coordinating Center
J Acquir Immune Defic Syndr 47:212-20. 2008.... - Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenzElena Ferrer
J Acquir Immune Defic Syndr 46:253-5. 2007 - [Treatment of opportunistic infections in adolescent and adult patients infected with the human immunodeficiency virus during the era of highly active antiretroviral therapy. AIDS Study Group (GESIDA) and National AIDS Plan Expert Committee]Daniel Podzamczer
Enferm Infecc Microbiol Clin 26:356-79. 2008..gesida.seimc.org)... - Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicinL Martin-Carbonero
Dept of Infectious Diseases, Hospital Carlos III, Madrid, Spain
Clin Infect Dis 47:410-7. 2008..However, this tumor still represents the most common cancer in this population...